Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Entinostat - EOC Pharma/Syndax Pharmaceuticals

Next Previous
Drug Profile

Entinostat - EOC Pharma/Syndax Pharmaceuticals

Alternative Names: EDP-103; EOC 103; KHK-2375; MS-27-275; MS-275; SND 275; SNDX-275

Latest Information Update: 21 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsui Pharmaceuticals; University of Tokyo
  • Developer EOC Pharma; Syndax Pharmaceuticals
  • Class Aniline compounds; Antineoplastics; Benzamides; Carbamates; Pyridines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered HER2 negative breast cancer
  • Phase I/II HER2 positive breast cancer
  • Suspended Bladder cancer; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Follicular lymphoma; Hodgkin's disease; Leukaemia; Malignant melanoma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Uveal melanoma

Most Recent Events

  • 29 May 2026 Efficacym adverse event and pharmacodynamics data from the phase II ENCORE 601 trial in Malignant Melanoma presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
  • 04 Mar 2026 Tianjin Medical University Cancer Institute and Hospital plans a phase II trial for HER2-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in April 2026 (PO) (NCT07441486)
  • 23 Jun 2025 Phase-I/II clinical trials in HER2-positive-breast-cancer(Late-stage disease, Recurrent, Metastatic disease, Second-line therapy or greater, Combination therapy) in China (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top